Herbst is the ensign professor of medicine, professor of pharmacology, chief of medical oncology, director of the Thoracic Oncology Research Program, and associate director for translational research at the Yale Cancer Center and Yale School of Medicine.He is best known for his work in the personalized therapy of non-small cell lung cancer, in particular the process of linking genetic abnormalities of cancer cells to novel therapies.Dr. Herbst's laboratory work has focused on immunotherapy angiogenesis; dual epidermal growth factor receptor /vascular endothelial growth factor receptor inhibition in NSCLC and targeting KRAS-activated pathways.His research has explored predictive biomarkers for the use of immunotherapy agents and is he serves as one of the principal investigators of the NCI lung cancer master protocol.Although activating the immune system has shown to be a successful goal for cancer treatment, he did note that it can result in immune-related adverse effects in various body systems:He is also a member of the Oncology Report editorial board.
Events - Primer's event detection algorithm clusters and summarizes multiple documents describing real-world events.
Mentions - Mentions are snippets of text that map to a person.
Docs - The number of documents that match to a person in Primer's corpus of news articles.
Full tech explainer here.
Remember to check the sources and follow Wikipedia's guidelines.
Yale Cancer Center
More patients with advanced non-small-cell lung cancer could benefit from pembrolizumab, says Professor Roy Herbst, Chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital at Yale-New Haven, presenting promising results from the pivotal phase 2/3 KEYNOTE-010 trial at the first ESMO Asia Congress in Singapore ), in conjunction with a publication in The Lancet . "The topline results show that both groups of patients receiving pembrolizumab experience a survival benefit compared to docetaxel," Herbst said. "As expected, at the highest biomarker expression, the results were even better with a hazard ratio of 0.54 and 0.50 at the two doses of pembrolizumab, respectively. "Data from the KEYNOTE-010 study suggests, that pembrolizumab would be given to all patients with PD-L1 expression and this could have an impact on current strategies for lung cancer," he concluded.
Another study found that an immunotherapy combo — the Bristol-Myers Squibb drugs Opdivo and Yervoy — worked better than chemo for delaying the time until cancer worsened in advanced lung cancer patients whose tumors have many gene flaws, as nearly half do. All of these immune therapy treatments worked for only about half of patients, but that's far better than chemo has done in the past. "We're not nearly where we need to be yet," said Dr. Roy Herbst, a Yale Cancer Center lung expert who had no role in the studies. Results were discussed Monday at an American Association for Cancer Research conference in Chicago and published by the New England Journal of Medicine.